GnRH Agonist Triggering of Ovulation Replacing hCG: A 30-Year-Old Revolution in IVF Practice Led by Rambam Health Care Campus
نویسندگان
چکیده
Final oocyte maturation is a crucial step in in vitro fertilization, traditionally achieved with a single bolus of human chorionic gonadotropin (hCG) given 36 hours before oocyte retrieval. This bolus exposes the patient to the risks of ovarian hyperstimulation syndrome (OHSS), particularly in the face of ovarian hyper-response to gonadotropins. Although multiple measures were developed to prevent OHSS, gonadotropin-releasing hormone (GnRH) agonist triggering is now globally recognized as the best approach to achieve this goal. The first report on the use of GnRH agonist as ovulation trigger in the context of OHSS prevention came from Rambam Health Care Campus, Haifa, Israel and appeared in 1988. This review details the events that culminated in worldwide acceptance of this measure and describes its benefit in the field of assisted reproductive technology.
منابع مشابه
I-27: GnRH Agonist Triggering and Luteal Phase Support
Background GnRH agonist triggering is one of the strategies for ovulation triggering and final maturation of oocytes. So , should be notice for luteal phase support in these cycles. At the first it was began for prevention of severe OHSS but it was associated with luteal phase problem and lower pregnancy rate due to luteolysis effects of GnRH agonists. So, two other alternative strategies have ...
متن کاملhCG Triggering in ART: An Evolutionary Concept
Human chorionic gonadotropin (hCG) is no longer a single, omnipotent ovulation triggering option. Gonadotropin releasing hormone (GnRH) agonist, initially presented as a substitute for hCG, has led to a new era of administering GnRH agonist followed by hCG triggering. According to this new concept, GnRH agonist enables successful ovum maturation, while hCG supports the luteal phase and pregnanc...
متن کاملGnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article
Routinely, a bolus of 5.000-10.000 IU human chorionic gonadotropin (hCG) is used for the final follicular maturation and ovulation as a standard method. HCG has the same effect of luteinizing hormone (LH) with long half-life. It has the long lutheotrophic effect which increases the risk of ovarian hyper stimulation syndrome (OHSS). Recently, gonadotropin-releasing hormone agonist (GnRH-a) trigg...
متن کاملThe luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives.
In stimulated IVF/intracytoplasmic sperm injection cycles, the luteal phase is disrupted, necessitating luteal-phase supplementation. The most plausible reason behind this is the ovarian multifollicular development obtained after ovarian stimulation, resulting in supraphysiological steroid concentrations and consecutive inhibition of LH secretion by the pituitary via negative feedback at the le...
متن کاملI-25: GnRHa Trigger State of the ART -Towards the OHSS Free Clinic
Human chorionic gonadotropin (hCG) has been used as a surrogate for the mid-cycle LH surge for several decades. Due to structural and biological similarities with LH, hCG binds to and activates the same receptor - the LH/hCG receptor. However, despite the fact that hCG effectively secures final oocyte maturation and ovulation, its use as a surrogate for LH has got several drawbacks - first and ...
متن کامل